

Karen Dilks

Lord Mayor's Suite Civic Centre Barras Bridge Newcastle Upon Tyne NE1 8QH **National Medical Director**

NHS England Wellington House 133-155 Waterloo Road London SE1 8UG

29 April 2024

Dear Coroner,

Re: Regulation 28 Report to Prevent Future Deaths – James Atkinson who died on 10 July 2020.

Thank you for your Report to Prevent Future Deaths (hereafter "Report") dated 26 January 2024 concerning the death of James Atkinson on 10 July 2020. In advance of responding to the specific concerns raised in your Report, I would like to express my deep condolences to James' family and loved ones. NHS England are keen to assure the family and the coroner that the concerns raised about James' have been listened to and reflected upon.

NHS England has a Clinical Reference Group (CRG) that provides clinical advice and leadership for both Specialised Immunology and Specialised Allergy services. The membership includes clinicians, commissioners, public health experts and Patient and Public Voice members. They use their combined knowledge and expertise to advise NHS England on the optimal arrangements for the commissioning of specialised services. This includes developing national standards for services delivering specialised care to patients with allergies in the form of national service specifications and policies. The CRG commenced a review of the current published Specialist Allergy Service Specification in May 2023, which is expected to be complete by Summer 2024.

This particular case highlights the need for supporting young people as they transition from children to adult services. The updated service specification will strengthen the requirement for providers of specialist allergy services to plan, organise and implement transition support and care, for example by holding joint annual review meetings with the child/young person, their family/carers, and the children's or adult service. The aim is to ensure that young people are equal partners in planning and decision making and that their preferences and wishes are central throughout transition and transfer. The specification work will include reviewing existing requirements in relation to self-care and the provision of service user/carer information and the updated specification is also likely to set out the requirement for specialist centres to develop documented personal management plans for patients with allergic conditions, with guidance for ongoing primary or specialist care.

The Executive Area Director (Tees Valley and Central) within the North East and North Cumbria Integrated Care Board (NENC ICB) have also reviewed the concerns raised in your report. They have advised that learnings were taken, and changes and

improvements have been made by the Practice involved in this matter. The learning will be shared with other practices across NENC ICB to maximise learning and improvement opportunities for the improvement of patient safety.

The following links to guidance were also shared by NHS England's North East and Yorkshire Regional Chief Pharmacist to reinforce guidance and learning:

- Adrenaline auto-injectors (AAIs): new guidance and resources for safe use -GOV.UK (www.gov.uk)
- EpiPen®: Guidelines For Healthcare Professionals | EpiPen®

I would also like to provide further assurances on national NHS England work taking place around the Reports to Prevent Future Deaths. All reports received are discussed by the Regulation 28 Working Group, comprising Regional Medical Directors, and other clinical and quality colleagues from across the regions. This ensures that key learnings and insights around preventable deaths are shared across the NHS at both a national and regional level and helps us pay close attention to any emerging trends that may require further review and action.

Thank you for bringing these important patient safety issues to my attention and please do not hesitate to contact me should you need any further information.

Yours sincerely,

National Medical Director